跳转至内容
Merck

1134299

USP

Citalopram Related Compound F

United States Pharmacopeia (USP) Reference Standard

别名:

(RS)-Dimethyl(1-methyl-3,3-diphenylallyl)amine hydrochloride

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H21N · HCl
CAS号:
分子量:
287.83
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

citalopram

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

InChI

1S/C18H21N.ClH/c1-15(19(2)3)14-18(16-10-6-4-7-11-16)17-12-8-5-9-13-17;/h4-15H,1-3H3;1H

InChI 密鑰

ZVTAYVQUGPGRAF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Citalopram Related Compound F USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Citalopram Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

象形圖

Skull and crossbones

訊號詞

Danger

危險聲明

防範說明

危險分類

Acute Tox. 3 Oral

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

B Ebert et al.
Pharmacology & toxicology, 82(3), 157-160 (1998-04-29)
The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketobemidone and a spasmolytic compound, (RS)-3-dimethylamino-1,1-diphenylbut-1-ene, hydrochloride (A29), in a one to five ratio. Using
Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.
N Grosman
Acta pharmacologica et toxicologica, 50(1), 78-80 (1982-01-01)
M Kjaer et al.
Acta oncologica (Stockholm, Sweden), 27(5), 583-589 (1988-01-01)
Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture. The
P Anderson et al.
European journal of clinical pharmacology, 19(3), 217-223 (1981-02-01)
The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intravenous administration of Ketogin 2 ml, containing ketobemidone chloride 10 mg, and a spasmolytic compound N,N-dimethyl-3,3-diphenyl-1-methylallylamine
J C Raeder et al.
Acta anaesthesiologica Scandinavica, 30(7), 502-506 (1986-10-01)
A double-blind comparison of the effect of Ketogan (ketobemidone and A-29, an anticholinergic and spasmolytic agent) and morphine + scopolamine as premedication was performed in 113 women admitted for abortion and in 114 women admitted for gynaecological dilatation and curettage.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门